Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.
about
Incidence and predictors of first line antiretroviral regimen modification in western KenyaReasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort AnalysisSingle Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive IndividualsPredictors of Treatment Failure in HIV-Positive Children Receiving Combination Antiretroviral Therapy: Cohort Data From Mozambique and Uganda.Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015.Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapyPractical methods for competing risks data: a review.Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patientsImpact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection.Assessing the performance of a computer-based policy model of HIV and AIDSWomen experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in GhanaIncreasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression.Psychometric properties of a Symptom Management Self-Efficacy Scale for women living with HIV/AIDS.Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in CanadaTolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study.Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South AfricaThe Reason for Regimen Change Among HIV/AIDS Patients Initiated on First Line Highly Active Antiretroviral Therapy in Southern Ethiopia.Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts.A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.Durability of adherence to antiretroviral therapy on initial and subsequent regimens.Temporal trends in the discontinuation of first-line antiretroviral therapyAntiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996-2011Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen SwitchingDiscontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized TherapyEfavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysisOptimal HAART adherence over time and time interval between successive visits: their association and determinantsToxicity-related antiretroviral drug treatment modifications in individuals starting therapy: a cohort analysis of time patterns, sex, and other risk factors.Factors associated with 10 years of continuous viral load suppression on HAART.Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.Gender differences in discontinuation of antiretroviral treatment regimens.Increases in duration of first highly active antiretroviral therapy over time (1996-2009) and associated factors in the Multicenter AIDS Cohort Study.Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy.Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review.Long-term effect of different classes of highly active antiretroviral therapy on transaminases.
P2860
Q28541822-C9C574B0-5EE8-46A0-90F2-8F8DC1502EB7Q28546795-E6C717A5-AEB1-479F-ADB6-36C29B3FAA14Q28554250-FE824055-6F2C-469E-9345-9B99C3C140FAQ30997469-60C17A6E-3E3E-481D-9583-0934F521D53CQ33598309-6FB5C918-5AD7-4DAF-AB6E-5EFBC56A0C75Q33634625-10852A85-CFEB-4DF9-B641-764A4700D3E3Q33689432-0863C7B4-8485-48B3-96D7-DF0D2F3B6A27Q33788920-E8D3B17F-E9F1-4529-A649-3F0C953591E3Q33846390-8AB0B2FF-528D-4121-A452-0D0E9DBBD35AQ33927106-55EABF80-C12C-4D65-8822-F41E2FBB9972Q34034101-7397958A-EC25-4033-A85F-005C0A74F91EQ34115343-351E63BC-7571-421E-98E6-001CE6F1EFBEQ34148055-6D2C63AB-8AD7-44EA-A0D2-6C00B54D591CQ34427807-FE08BB31-ECCA-4602-964B-E3C8752A3BDEQ34614542-BD8C04A5-92BF-487F-A84E-8223DA8C9CEFQ34709059-A89BE90B-81C0-4A07-86EB-F90DB5F84266Q34989696-CCA6E46D-1FE8-41CE-A6AA-68CB2534E4A9Q35047307-53CB8B1C-EB9E-4FD7-9B34-2BD538796B40Q35102751-22F9FD6B-B6FA-489A-8B78-78ABC340D550Q35109881-CC0E483B-DB8E-456F-ACCB-96052620F07AQ35787655-2C45B7F8-F49E-434C-91C2-2D9627950AB2Q35843765-D712D0D2-C5D3-49E2-A0DF-17FF0C38EC00Q35872422-AE27913D-C5FC-4630-98DF-F698A8607702Q35990464-C54B271E-5822-491D-B9D7-2D5DDFC51C2BQ36093602-9D345EBC-4364-4822-8ECB-0D776DD8465AQ36463711-855E7673-6256-48A0-B1A9-CFBF8F924AAEQ36472359-02F01C18-E46E-4CA7-9FE0-0CE1C4F22406Q36628396-A94D8D4B-5051-4922-B36A-04CC9BE41CBDQ36723853-6499A3B1-3A9E-444A-86B4-78F0F6878394Q36733621-D5577F1A-BB27-4BC3-A4C0-FC48A0F559B4Q36778245-1C1364A5-AAEB-40FF-8808-EE66F576A29FQ36954711-BB492EAE-3172-4767-841F-177FBA5C6E74Q37118025-AF9A2BF7-83DE-4649-9FA7-2195B376E3A4Q37237006-4CB1E930-E7E7-45DA-A3C2-1F042CCDBCFDQ37388428-603AEF47-D893-4195-9BCD-77A8E892992AQ37440855-786A22C5-48FF-42EA-82F7-1A7DA34FEA9DQ37497586-2317A629-C13C-49B2-A23B-1D4C5DCAC327Q37605850-DF63A224-D15B-4924-A551-1E253CB109C1Q37896165-06CA8571-6D36-4097-AF93-BEA3D3B35FDFQ38327191-24A17A7E-A8C0-461A-850C-3DEE459288EB
P2860
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Reasons for modification and d ...... rom a single treatment centre.
@ast
Reasons for modification and d ...... rom a single treatment centre.
@en
type
label
Reasons for modification and d ...... rom a single treatment centre.
@ast
Reasons for modification and d ...... rom a single treatment centre.
@en
prefLabel
Reasons for modification and d ...... rom a single treatment centre.
@ast
Reasons for modification and d ...... rom a single treatment centre.
@en
P2093
P1433
P1476
Reasons for modification and d ...... from a single treatment centre
@en
P2093
A N Phillips
C Chaloner
M A Johnson
P304
P356
10.1097/00002030-200101260-00007
P407
P577
2001-01-01T00:00:00Z